Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Marc Garnier

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Oncogene|May 11, 2018
Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibitionClare E Weeden, Casey Ah-Cann, Aliaksei Z Holik, et al.
Autophagy|May 13, 2016
BAX-BAK1-independent LC3B lipidation by BH3 mimetics is unrelated to BH3 mimetic activity and has only minimal effects on autophagic fluxBoris Reljic, Stephanie Conos, Erinna F Lee, et al.
Cell Death & Disease|July 7, 2017
The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XLAlex Rd Delbridge, Brandon J Aubrey, Craig Hyland, et al.
Blood|July 29, 2016
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Jia-Nan Gong, Tiffany Khong, David Segal, et al.
Nature Communications|November 23, 2021
Human RIPK3 maintains MLKL in an inactive conformation prior to cell death by necroptosisYanxiang Meng, Katherine A Davies, Cheree Fitzgibbon, et al.
Molecular Cancer Therapeutics|June 15, 2017
Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell CarcinomaClare E Weeden, Aliaksei Z Holik, Richard J Young, et al.
Elife|November 3, 2016
Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancerStephanie Berger, Erik Procko, Daciana Margineantu, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain InhibitorsPhillip P Sharp, Jean-Marc Garnier, Tamas Hatfaludi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2014
Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell deathJoanne M Hildebrand, Maria C Tanzer, Isabelle S Lucet, et al.
ACS Chemical Biology|September 9, 2020
Potent Inhibition of Necroptosis by Simultaneously Targeting Multiple Effectors of the PathwayCatia L Pierotti, Maria C Tanzer, Annette V Jacobsen, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Oncogene|May 11, 2018
Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibitionClare E Weeden, Casey Ah-Cann, Aliaksei Z Holik, et al.
Autophagy|May 13, 2016
BAX-BAK1-independent LC3B lipidation by BH3 mimetics is unrelated to BH3 mimetic activity and has only minimal effects on autophagic fluxBoris Reljic, Stephanie Conos, Erinna F Lee, et al.
Cell Death & Disease|July 7, 2017
The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XLAlex Rd Delbridge, Brandon J Aubrey, Craig Hyland, et al.
Blood|July 29, 2016
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Jia-Nan Gong, Tiffany Khong, David Segal, et al.
Nature Communications|November 23, 2021
Human RIPK3 maintains MLKL in an inactive conformation prior to cell death by necroptosisYanxiang Meng, Katherine A Davies, Cheree Fitzgibbon, et al.
Molecular Cancer Therapeutics|June 15, 2017
Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell CarcinomaClare E Weeden, Aliaksei Z Holik, Richard J Young, et al.
Elife|November 3, 2016
Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancerStephanie Berger, Erik Procko, Daciana Margineantu, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain InhibitorsPhillip P Sharp, Jean-Marc Garnier, Tamas Hatfaludi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2014
Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell deathJoanne M Hildebrand, Maria C Tanzer, Isabelle S Lucet, et al.
ACS Chemical Biology|September 9, 2020
Potent Inhibition of Necroptosis by Simultaneously Targeting Multiple Effectors of the PathwayCatia L Pierotti, Maria C Tanzer, Annette V Jacobsen, et al.
Pageof 2